All In MedTech

Device Trial Radar · NCT05413304

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

5

Actual

Start

Apr 7, 2023

Primary completion

Oct 21, 2025

Study completion Sep 1, 2027

Sponsor

Sponsor type
NIH
First posted
Jun 10, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults. Most people with these tumors survive less than 2 years. Researchers want to see if an anticancer drug (abemaciclib) can help. Objective: To see if researchers can measure how much abemaciclib is in a person's brain tumor and brain fluid after they take the drug for a few days. Eligibility: People aged 18 to 39 with recurrent high-grade glioma or diffuse midline glioma. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Tests of heart function Imaging scans of the brain, with a contrast agent Screening tests will be repeated during the study. Participants will also have chest X-rays. Participants will take abemaciclib by mouth twice a day for 4 and a half days. Participants will undergo surgery. They will have either a tumor biopsy (a needle will be inserted to remove a small piece of tissue) or a surgical resection (part or all of the tumor will be removed). A small tube (catheter) will be placed in their brain for 48 hours to collect fluid samples. They will have a neurological exam every few hours while the tube is in place. Two days later, the tube will be removed without surgery. Participants will stay in the hospital for about 4 days for treatment. Based on the results of abemaciclib levels in the brain, participants may keep taking abemaciclib and another drug (temozolomide) by mouth until their cancer gets worse or they have bad side effects. While taking these two drugs, participants will come back to the clinic for follow-up routinely. They will be followed by the study for life....

Conditions

  • Glioma

Interventions

  • Pre-operative abemaciclibDrug

    Pre-operatively for 4.5 days; 200mg twice daily (9 total doses)

  • Device for Cerebral Fluid Dialysate CollectionDevice

    Post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48 hours to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib

  • Ashion Analytics GEM ExTraDevice

    Resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets

  • abemaciclib + temozolomideDrug

    Abemaciclib 150mg by mouth (po) twice a day (BID) and temozolomide 200mg/m\^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m\^2 po daily x 5 days for cycle 1)

  • TemozolomideDrug

    Temozolomide 150mg/m\^2 by mouth (po) daily x 5 days for cycle 1

  • Brain MRIDiagnostic test

    Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), as clinically indicated at catheter removal Day 7 (\>48 hours post op), maintenance therapy (after every 3 cycles), and post treatment (safety and long-term follow-up) as clinically indicated.

  • Brain CTDiagnostic test

    Microdialysis (catheter in place) Day 5 and Day 6, and as clinically indicated at catheter removal Day 7 (\>48 hours post op).

  • EKGDiagnostic test

    Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (\>48 hours post op).

  • Chest X-rayDiagnostic test

    Baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (\>48 hours post op).

  • Biopsy/resectionProcedure

    Microdialysis (catheter in place) Day 5 and Day 6.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence IntervalTime frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
  2. Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence IntervalTime frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
  3. Number of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving AbemaciclibTime frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.